Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin B - Supernus Pharmaceuticals

Next Previous
Drug Profile

Botulinum toxin B - Supernus Pharmaceuticals

Alternative Names: AN 072; BoNT/B; BotB; Botulinum toxin type B; E 2014; Myobloc; NerBloc; Neurobloc; RimabotulinumtoxinB

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Solstice Neurosciences
  • Developer Eisai Co Ltd; Sloan Pharma; Solstice Neurosciences; Supernus Pharmaceuticals; US WorldMeds
  • Class Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dystonia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Sialorrhoea; Torticollis
  • Phase II/III Muscle spasticity

Most Recent Events

  • 09 Dec 2022 Withdrawn for Torticollis in European Union (IM)
  • 16 Nov 2021 Phase-II/III clinical trials in Muscle spasticity (In adults, In the elderly) in Czech Republic (IM) (NCT04815967)
  • 16 Nov 2021 Supernus Pharmaceuticals in collaboration with Solstice Neurosciences initiates enrolment in a phase II/III trial in Muscle spasticity (In adults, In the elderly) in USA (IM, Injection) (NCT04815967)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top